Sara Y.\u00a0Tartof,\u00a0Timothy B.\u00a0Frankland,\u00a0Jeff M.\u00a0Slezak,\u00a0et al<\/h3>\n\n\n\nJAMA.\u00a0<\/em>Published online September 15, 2023. doi:10.1001\/jama.2023.17473<\/h3>\n\n\n\nWild-type COVID-19 mRNA vaccines were recommended for children aged 6 months through 4 years on June 18, 2022.1<\/a><\/sup>However, COVID-19 vaccine uptake in this age group is low, with less than 5% completing a primary vaccine series as of May 24, 2023.2<\/a><\/sup> Only 1 study has described the association between COVID-19 vaccination and disease outcomes among children younger than 5 years, but it did not include children younger than 3 years or evaluate medically attended outcomes.3<\/a><\/sup> This study estimated the association between receipt of wild-type BNT162b2 vaccine (Pfizer) and medically attended COVID-19 outcomes among children younger than 5 years.<\/a><\/p>\n\n\n\nMethods<\/p>\n\n\n\n
Similar to previous studies,4<\/a><\/sup> a test-negative case-control design compared the risk of vaccination between COVID-19 cases and test-negative controls. We included patients aged 6 months through 4 years at Kaiser Permanente Southern California (KPSC) who were diagnosed with acute respiratory infection (ARI; eTable in Supplement 1<\/a>) and tested for SARS-CoV-2 using polymerase chain reaction (PCR) testing in the emergency department (ED) or urgent care (UC) or in-person outpatient setting from July 23, 2022, through May 19, 2023. Cases were defined as those with a positive SARS-CoV-2 PCR test result and controls had negative test results and no evidence of a test result positive for SARS-CoV-2 in the past 90 days (Supplement 1<\/a>). Vaccination status was determined based on receipt of vaccine 14 days or more before COVID-19 exposure. BNT162b2 is given as a 3-dose series (3 \u03bcg\/dose) in this age group, with dose 2 given 3 to 8 weeks after dose 1 and dose 3 given at least 8 weeks after dose 2. Patients who did not follow the dosing schedule, received only 1 or more than 3 doses of BNT162b2, or received any other COVID-19 vaccine were excluded. Odds ratios (ORs) and 95% CIs were calculated from logistic regression models that included date of encounter, age, sex, race and ethnicity, pediatric risk score, and history of SARS-CoV-2 infection (separately for each encounter type to approximate outcome severity and separately by number of doses; Supplement 1<\/a>). The 95% CIs were calculated using the Wald method. Analyses were performed using SAS, version 8.2 (SAS Institute). This study was approved by the KPSC institutional review board, which waived requirement for informed consent.<\/a><\/p>\n\n\n\nResults<\/p>\n\n\n\n
Of 176\u202f773 ED, UC, or outpatient ARI encounters in patients aged 6 months to 4 years, 24\u202f261 met inclusion criteria (11\u202f615 [48%] in the ED, 7074 [29%] in UC, and 5572 [23%] outpatient) during the study period. Overall, 2337 (10%) had positive test results for SARS-CoV-2 and 1457 (6%) were vaccinated. A total of 76 of 2337 cases (3.3%) and 1381 of 21\u202f924 controls (6.3%) were vaccinated with 2 or 3 doses of BNT162b2 (Table<\/a>). Among those who received only 2 doses, the median (range) number of days since dose 2 was 59 (14-277), since dose 3 was 74 (14-244), and between doses 2 and 3 was 61 (56-163).<\/a><\/p>\n\n\n\nCompared with unvaccinated children, the adjusted OR for children who received 2 or 3 doses of BNT162b2 was 0.70 (95% CI, 0.52-0.93) for a COVID-19\u2013related ED or UC encounter, 0.60 (95% CI, 0.39-0.92) for outpatient visits, and 0.67 (95% CI, 0.53-0.85) for either outcome (Figure<\/a>). The risk of a positive test result for SARS-CoV-2 during ED or UC and outpatient encounters was 0.56 (95% CI, 0.40-0.77) for those who received 2 doses vs 0.88 (95% CI, 0.62-1.25) for those who received 3 doses.<\/p>\n\n\n\n![\"\"\/](\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/0\/jld230064f1_1694608066.59991.png?Expires=1697842074&Signature=bEWfq1NowXYsetcJ5CU~5CAyAM61nQGMUOKaLMSaLSpLdoyeWtaiJEKGfw2WZPfMlRpWcF~yzEPTz0uEOxasDD12~qLYGU3RW1njzLQK07OE9b9ZmaZz-BOpGDUpjQOWRyeTMYVBWe9quG5SfU9hOnFABiSoGAgyIsD1n92SNsOEj1cwHeJJ45u0vvW0C-P7JXB4AHxXPNGWRK4oSgfL0tIfUHBEyFiMzPjeyyCKic0Lcc0pCER~Cn8KVhxIg7Tr0yiREtvaYiFweRBjmSXJv-cfP8euiaJp9riC1qhxjaqS~46c1ap8EvATMGPRmrTCDAht~SG2J0lqteK1zzcVKg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\")
<\/figure>\n\n\n\n![\"\"\/](\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/0\/jld230064t1_1694608066.54873.png?Expires=1697842074&Signature=dBZIQCxj6zT3rXdGqXBCwUhkWcu6l0hWg9s2ZdjADVuS~qIVzXot2UGU5znp4panELBA5-n5T4R8Sl9qOKWwJTAP05L32Ek4bUIpNh4Ah-VyV2VCUq7rVo1FuEA8~s549j0WIA6Ar7sH2l9MxxwDwURUHW4w402a4uZTGXycs29DcLix2SQF5ENNa5hsZbpLGFODm0lohbhPY~pmCFbxKB9-et4fI7OyX5Xi3UlVnDbzK0WMiA3airP0NgohmeVKxg8kXQAt89g-2GMMb0BPzoeSm2J4dWZQ6e7akm4JzqHVuO4Mfh3Hoy6Mgj7YnUKwTikelkI5DsDLG4jf3UWMBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\")
<\/figure>\n\n\n\nDiscussion<\/p>\n\n\n\n
Receiving at least 2 doses of wild-type BNT162b2 vaccine was associated with a reduced risk of COVID-19 ED or UC and outpatient visits in children younger than 5 years. The risk of SARS-CoV-2 encounters appeared lower for those with 2 vs 3 doses of BNT162b2, albeit with wide CIs, which is likely due to more immune-evasive Omicron sublineages (eg, BQ.1-related and XBB-related strains) becoming dominant by the time young children received their third dose5<\/a><\/sup> and longer median time since dose 3 compared with dose 2. The OR of 0.67 is equivalent to vaccine effectiveness (1 minus the OR) of 33%, which is lower than the approximately 70% efficacy against symptomatic COVID-19 seen in a clinical trial when BA.2 sublineages were predominant.6<\/a><\/sup> Study limitations include the potential for unmeasured confounding, potential misclassification of prior infection or whether ARI encounters were truly related to COVID-19, and the restriction to only 1 mRNA product. Updated vaccines will likely be needed to maintain protection against contemporary Omicron strains in young children.<\/p>\n","protected":false},"excerpt":{"rendered":"Research Letter September 15, 2023 Rece […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24687"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24687"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24687\/revisions"}],"predecessor-version":[{"id":24688,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24687\/revisions\/24688"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Wild-type COVID-19 mRNA vaccines were recommended for children aged 6 months through 4 years on June 18, 2022.1<\/a><\/sup>However, COVID-19 vaccine uptake in this age group is low, with less than 5% completing a primary vaccine series as of May 24, 2023.2<\/a><\/sup> Only 1 study has described the association between COVID-19 vaccination and disease outcomes among children younger than 5 years, but it did not include children younger than 3 years or evaluate medically attended outcomes.3<\/a><\/sup> This study estimated the association between receipt of wild-type BNT162b2 vaccine (Pfizer) and medically attended COVID-19 outcomes among children younger than 5 years.<\/a><\/p>\n\n\n\n Methods<\/p>\n\n\n\n Similar to previous studies,4<\/a><\/sup> a test-negative case-control design compared the risk of vaccination between COVID-19 cases and test-negative controls. We included patients aged 6 months through 4 years at Kaiser Permanente Southern California (KPSC) who were diagnosed with acute respiratory infection (ARI; eTable in Supplement 1<\/a>) and tested for SARS-CoV-2 using polymerase chain reaction (PCR) testing in the emergency department (ED) or urgent care (UC) or in-person outpatient setting from July 23, 2022, through May 19, 2023. Cases were defined as those with a positive SARS-CoV-2 PCR test result and controls had negative test results and no evidence of a test result positive for SARS-CoV-2 in the past 90 days (Supplement 1<\/a>). Vaccination status was determined based on receipt of vaccine 14 days or more before COVID-19 exposure. BNT162b2 is given as a 3-dose series (3 \u03bcg\/dose) in this age group, with dose 2 given 3 to 8 weeks after dose 1 and dose 3 given at least 8 weeks after dose 2. Patients who did not follow the dosing schedule, received only 1 or more than 3 doses of BNT162b2, or received any other COVID-19 vaccine were excluded. Odds ratios (ORs) and 95% CIs were calculated from logistic regression models that included date of encounter, age, sex, race and ethnicity, pediatric risk score, and history of SARS-CoV-2 infection (separately for each encounter type to approximate outcome severity and separately by number of doses; Supplement 1<\/a>). The 95% CIs were calculated using the Wald method. Analyses were performed using SAS, version 8.2 (SAS Institute). This study was approved by the KPSC institutional review board, which waived requirement for informed consent.<\/a><\/p>\n\n\n\n Results<\/p>\n\n\n\n Of 176\u202f773 ED, UC, or outpatient ARI encounters in patients aged 6 months to 4 years, 24\u202f261 met inclusion criteria (11\u202f615 [48%] in the ED, 7074 [29%] in UC, and 5572 [23%] outpatient) during the study period. Overall, 2337 (10%) had positive test results for SARS-CoV-2 and 1457 (6%) were vaccinated. A total of 76 of 2337 cases (3.3%) and 1381 of 21\u202f924 controls (6.3%) were vaccinated with 2 or 3 doses of BNT162b2 (Table<\/a>). Among those who received only 2 doses, the median (range) number of days since dose 2 was 59 (14-277), since dose 3 was 74 (14-244), and between doses 2 and 3 was 61 (56-163).<\/a><\/p>\n\n\n\n Compared with unvaccinated children, the adjusted OR for children who received 2 or 3 doses of BNT162b2 was 0.70 (95% CI, 0.52-0.93) for a COVID-19\u2013related ED or UC encounter, 0.60 (95% CI, 0.39-0.92) for outpatient visits, and 0.67 (95% CI, 0.53-0.85) for either outcome (Figure<\/a>). The risk of a positive test result for SARS-CoV-2 during ED or UC and outpatient encounters was 0.56 (95% CI, 0.40-0.77) for those who received 2 doses vs 0.88 (95% CI, 0.62-1.25) for those who received 3 doses.<\/p>\n\n\n\n Discussion<\/p>\n\n\n\n Receiving at least 2 doses of wild-type BNT162b2 vaccine was associated with a reduced risk of COVID-19 ED or UC and outpatient visits in children younger than 5 years. The risk of SARS-CoV-2 encounters appeared lower for those with 2 vs 3 doses of BNT162b2, albeit with wide CIs, which is likely due to more immune-evasive Omicron sublineages (eg, BQ.1-related and XBB-related strains) becoming dominant by the time young children received their third dose5<\/a><\/sup> and longer median time since dose 3 compared with dose 2. The OR of 0.67 is equivalent to vaccine effectiveness (1 minus the OR) of 33%, which is lower than the approximately 70% efficacy against symptomatic COVID-19 seen in a clinical trial when BA.2 sublineages were predominant.6<\/a><\/sup> Study limitations include the potential for unmeasured confounding, potential misclassification of prior infection or whether ARI encounters were truly related to COVID-19, and the restriction to only 1 mRNA product. Updated vaccines will likely be needed to maintain protection against contemporary Omicron strains in young children.<\/p>\n","protected":false},"excerpt":{"rendered":" Research Letter September 15, 2023 Rece […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24687"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24687"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24687\/revisions"}],"predecessor-version":[{"id":24688,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24687\/revisions\/24688"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/figure>\n\n\n\n<\/figure>\n\n\n\n